Pharma stocks face Q4 reality check amid global headwinds
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The study was conducted by PwC India in line with ISO 14040 and ISO 14044 protocols
Marking three years of the National Diagnostics Catapult (NDxC), the conclave launched the Impact Report and unveiled environmental surveillance kits
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
Subscribe To Our Newsletter & Stay Updated